Skip to main content

Table 5 Demographic, treatment centre, insurance coverage and drug characteristics comparison between on-label and off-label encounters

From: Off-label use of cancer therapies in women diagnosed with breast cancer in the United States

Variable Variable category Off-label (%)
Age* 15-49 621 (16.2%)
  50-64 396 (10.4%)
  65-74 432 (9.7%)
  75+ 187 (7.4%)
Ethnicity* Caucasian 1113 (10.3%)
  African American 185 (13.0%)
  Other 95 (15.3%)
  Unknown 243 (14.4%)
Marital status Married 338 (11.0%)
  Other 1293 (11.3%)
  Unknown 5 (10.4%)
Prescription drug coverage* Medicare 209 (9.5%)
  Medicaid 81 (10.4%)
  HMO/PPO 24 (6.9%)
  Blue Cross 65 (15.3%)
  Self-pay 21 (11.0%)
  Other 75 (12.3%)
  Unknown 1161 (11.6%)
Census region* Midwest 255 (8.9%)
  South 264 (11.4%)
  Northeast 1088 (12.0%)
  West 29 (9.0%)
Bed size* 1-99 477 (16.2%)
  100-199 48 (5.7%)
  200-299 315 (10.0%)
  300-499 234 (9.4%)
  500+ 562 (10.9%)
Physician type* Specialists 751 (10.9%)
  Surgeons 22 (5.9%)
  Generalists 28 (6.3%)
  Unknown 835 (12.1%)
Number of approved indications* 1-2 1395 (27.6%)
  3-4 206 (3.1%)
  5-7 34 (9.5%)
  8+ 1 (0.0%)
Date of FDA approval* Before 1981 130 (3.2%)
  1981-1990 602 (78.7%)
  1991-2000 635 (7.8%)
  2001-2009 269 (16.1%)
  1. *Differences amongst categories for this variable are significantly different (p < 0.00001) based on a chi-square test of homogeneity.
  2. Expressed as the number and percentage of off-label encounters.
  3. Expressed as the number and percentage of off-label encounters.